Non-small cell lung cancer metastatic
RecruitingStudy of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer
Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer
- Disease:Non-small cell lung cancer metastatic
- Substances:Osimertinib
Belgium- Participants:18–64 years · 65+ years
- Substances:Osimertinib
- Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

